Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors

Checkpoint inhibitors (CIs) are highly effective but can induce severe immune-related adverse events (irAEs), which cannot be predicted. We investigated whether human leukocyte antigen (HLA) genes predispose to developing of irAEs during therapy and thus hold a predictive role.

Source: European Journal of Cancer - December 6, 2018 Category: Cancer & Oncology Authors: Omar Hasan Ali, Fiamma Berner, David Bomze, Mirjam F ässler, Stefan Diem, Antonio Cozzio, Markus Jörger, Martin Früh, Christoph Driessen, Tobias L. Lenz, Lukas Flatz Tags: Original Research Source Type: research